
Hubing Shi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3796907/publications.pdf Version: 2024-02-01



HURING SHL

#	Article	IF	CITATIONS
1	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010, 468, 973-977.	13.7	1,944
2	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480, 387-390.	13.7	1,298
3	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery, 2014, 4, 80-93.	7.7	836
4	Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications, 2012, 3, 724.	5.8	567
5	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell, 2015, 162, 1271-1285.	13.5	516
6	Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 2015, 520, 368-372.	13.7	389
7	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. Cancer Cell, 2015, 27, 240-256.	7.7	299
8	Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nature Biomedical Engineering, 2019, 3, 306-317.	11.6	279
9	MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine, 2012, 18, 1239-1247.	15.2	266
10	Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition. Cancer Research, 2011, 71, 5067-5074.	0.4	206
11	HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity. Nature Chemical Biology, 2019, 15, 42-50.	3.9	189
12	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery, 2014, 4, 69-79.	7.7	141
13	Preexisting <i>MEK1</i> Exon 3 Mutations in <i>V600E/K BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2012, 2, 414-424.	7.7	91
14	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology, 2019, 10, 990.	2.2	86
15	Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 48.	1.3	63
16	<p>Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas</p> . OncoTargets and Therapy, 2020, Volume 13, 1311-1319.	1.0	59
17	JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discovery, 2016, 2, 16028.	3.1	57
18	PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. Oncolmmunology, 2017, 6, e1327494.	2.1	52

Нивінд Ѕні

#	Article	IF	CITATIONS
19	A novel pan ancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic. Cancer Science, 2019, 110, 2941-2959.	1.7	52
20	Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene, 2022, 41, 191-203.	2.6	37
21	MAPKâ€Targeted Drug Delivered by a pHâ€Sensitive MSNP Nanocarrier Synergizes with PDâ€1 Blockade in Melanoma without Tâ€Cell Suppression. Advanced Functional Materials, 2019, 29, 1806916.	7.8	34
22	Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis. Signal Transduction and Targeted Therapy, 2022, 7, 60.	7.1	31
23	A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. RSC Chemical Biology, 2021, 2, 192-205.	2.0	26
24	Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade. Journal of Controlled Release, 2021, 332, 194-209.	4.8	25
25	Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene, 2020, 39, 7106-7113.	2.6	22
26	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
27	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Frontiers in Pharmacology, 2019, 10, 726.	1.6	20
28	A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. Cell Chemical Biology, 2018, 25, 761-774.e5.	2.5	17
29	Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy. Molecular Biomedicine, 2020, 1, 12.	1.7	16
30	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Frontiers in Immunology, 2021, 12, 793831.	2.2	16
31	Inhibition of programmed cell death protein ligand-1 (PD-L1) by benzyl ether derivatives: analyses of conformational change, molecular recognition and binding free energy. Journal of Biomolecular Structure and Dynamics, 2019, 37, 4801-4812.	2.0	15
32	Detecting Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma. Methods in Molecular Biology, 2014, 1102, 163-174.	0.4	14
33	Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. Molecular Biomedicine, 2022, 3, 12.	1.7	12
34	The Evolution of Acquired Resistance to BRAFV600EÂkinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling. Journal of Investigative Dermatology, 2022, 142, 445-458.	0.3	11
35	AIDE: annotation-assisted isoform discovery with high precision. Genome Research, 2019, 29, 2056-2072.	2.4	10
36	BP[dG]-induced distortions to DNA polymerase and DNA duplex: A detailed mechanism of BP adducts blocking replication. Food and Chemical Toxicology, 2020, 140, 111325.	1.8	8

Hubing Shi

#	Article	IF	CITATIONS
37	Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Frontiers in Pharmacology, 2021, 12, 797852.	1.6	8
38	Theoretical insight into the photodeactivation pathway of the tetradentate Pt (II) complex with different inductive substituents. Applied Organometallic Chemistry, 2019, 33, e4879.	1.7	7
39	Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations. Frontiers in Molecular Biosciences, 2019, 6, 164.	1.6	5
40	Specifically targeting Mtb cell-wall and TMM transporter: the development of MmpL3 inhibitors. Current Protein and Peptide Science, 2021, 22, 290-303.	0.7	4
41	Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies. Frontiers in Pharmacology, 2020, 11, 591188.	1.6	1
42	Immunotherapy: MAPKâ€Targeted Drug Delivered by a pHâ€Sensitive MSNP Nanocarrier Synergizes with PDâ€1 Blockade in Melanoma without Tâ€Cell Suppression (Adv. Funct. Mater. 12/2019). Advanced Functional Materials, 2019, 29, 1970079.	7.8	0